ClinicalTrials.gg
CompletedNCT00145444Updated Feb 21, 2021

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

A Phase 3 interventional study of olanzapine and ziprasidone in Schizophrenia and Psychotic Disorders, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
54th of 94
100 · median 114
Started
2003
with 9 others
Phase 3
25 of 97
1 open now
Registered
19th of 97
by date
Lead sponsor
2 of 97
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 54th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2003, is one of 25 in phase 3, and was the 19th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical effect with improvements in all domains of cognitive function at 6 weeks (Daniel, 1999). Direct comparison of the two agents in a well-controlled double-blind fashion will allow an evaluation of the effect on cognitive function in the short and long-term management of patients with recent-onset schizophrenia, schizoaffective and schizophreniform disorder.

03

Conditions studied

  • Schizophrenia
  • Psychotic Disorders
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Duration of illness \< 5 years (according to and onset first psychotic episode); CGI severity score > 4 (moderately ill)
  • maximum exposure to antipsychotic treatment of =\< 16 weeks.

Exclusion criteria

Exclusion Criteria:

  • Concurrent treatment with antipsychotic agents =\< 12 hours prior to randomization
  • for depot agents a period of two weeks or one cycle, whichever is the longer, must occur between last administration and randomization
  • Treatment with antidepressants or mood stabilizers =\< 7 days of randomization
  • for MAOIs and moclobemide this period must =\< 2 weeks
  • for fluoxetine =\< 5 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The effect on cognitive function of ziprasidone and olanzapine in the management of recent-onset psychosis, measured as the difference in efficacy in a 8 week period from the baseline visit to the end of week 8 visit.

Secondary outcomes

  1. - to demonstrate effect on cognitive function of ziprasidone and olanzapine in the management of recent-onset psychosis, measured as the difference in efficacy over a 24-week and one year period from baseline visit to the end of week 24 and week 52 visit

07

Study locations

7 sites
  • Pfizer Investigational Site
    Antwerpen, B-2060, Belgium
  • Pfizer Investigational Site
    Duffel, B-2570, Belgium
  • Pfizer Investigational Site
    Kortenberg, B-3070, Belgium
  • Pfizer Investigational Site
    Ermelo, NL-3851 PB, Netherlands
  • Pfizer Investigational Site
    Groningen, NL-9713 GZ, Netherlands
  • Pfizer Investigational Site
    Nijmegen, NL-6525 GC, Netherlands
  • Pfizer Investigational Site
    Utrecht, 3584 CX, Netherlands
08

References and documents

Publications

  • Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, Verkes RJ, Kahn RS. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011 Mar;37(2):352-61. doi: 10.1093/schbul/sbp037. Epub 2009 Jun 19. PubMed 19542525 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 5, 2005
Start
Mar 2003
Completion
Nov 2005
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00145444
Responsible party
Sponsor
First posted
Sep 5, 2005
Start date
Mar 2003
Completion
Nov 2005
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olanzapine · Ziprasidone

Start the discussion